Calyxt, Inc. (CLXT)

Market Cap	7.45M
Revenue (ttm)	2.06M
Net Income (ttm)	-21.11M
Shares Out	46.78M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	423,656
Open	0.15
Previous Close	0.153
Day's Range	0.15 - 0.172
52-Week Range	0.125 - 2.65
Beta	1.84
Analysts	Buy
Price Target	5.61 (+3,401.9%)
Earnings Date	Nov 3, 2022

About CLXT

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. ...

• Industry: Biotechnology
• IPO Date: Jul 20, 2017
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CLXT

Full Company Profile

Financial Performance

In 2021, Calyxt's revenue was $25.99 million, an increase of 8.96% compared to the previous year's $23.85 million. Losses were -$29.20 million, -34.88% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CLXT stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 3,401.87% from the latest price.

Price Target

$5.61

(3,401.87% upside)

Analyst Consensus: Buy

Stock Forecasts